Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase 2 clinical trial of Lucid-MS, a “first-in-class” oral therapy designed to halt the progression of multiple sclerosis (MS) by protecting myelin, or the protective sheath around nerves in the brain. The Investigational New Drug (IND) application […]
The post Quantum Biopharma seeks FDA clearance to test Lucid-MS in patients appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com